Essilor buys majority stake in Transitions Optical

Article

Essilor International has acquired PPG Industries’ 51% stake in Transitions Optical.

 

Pinellas Park, FL-PPG Industries and Essilor International have struck a deal for Essilor to acquire PPG Industries’ 51% stake in Transitions Optical, according to news releases from PPG and Essilor. Essilor has held a 49% share of Transitions Optical since the business was founded in 1990.

Dave Cole, president, Transitions Optical, noted the history that PPG and Essilor have with Transitions: “We look forward to a continued strong relationship with PPG, because they will be providing ongoing research and development services and optical dyes to Transitions Optical under multi-year agreements with Essilor.

“This transaction is a continuation and enhancement of a relationship that has brought value to us and to our industry. There are tremendous opportunities to boost expansion of photochromic products, particularly in fast-growing markets,” Cole added.

The transaction is projected to close in the first half of 2014. Until then, it will be business as usual, Cole said. Transitions Optical will continue as a separately managed and operated business. According to the company, supplies of Transitions lenses will not be affected, and will continue to be available through other lens manufacturers.

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.